Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Michigan: - Saint Joseph Mercy Hospital — Ann Arbor, Michigan
- University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan
- Bronson Battle Creek — Battle Creek, Michigan
- McLaren Cancer Institute-Bay City — Bay City, Michigan
- McLaren Cancer Institute-Bloomfield — Bloomfield, Michigan
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of vorasidenib to placebo in combination with usual treatment, temozolomide, in treating patients with newly diagnosed grade 3 astrocytoma after radiation. Temozolomide is in a class of medications …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07215910
Sites in Michigan: - University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
- University of Michigan - Brighton Center for Specialty Care — Brighton, Michigan
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital — Grand Rapids, Michigan
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital — Grand Rapids, Michigan
- Trinity Health Grand Rapids Hospital — Grand Rapids, Michigan
Phase 3 Recruiting NIH
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04166409
Sites in Michigan: - C S Mott Children's Hospital — Ann Arbor, Michigan
- Children's Hospital of Michigan — Detroit, Michigan
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital — Grand Rapids, Michigan
- Corewell Health Children's — Royal Oak, Michigan
Phase 3 Recruiting Network
This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back …
Sponsor: Children's Oncology Group
NCT ID: NCT05382338
Sites in Michigan: - C S Mott Children's Hospital — Ann Arbor, Michigan
- Children's Hospital of Michigan — Detroit, Michigan
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital — Grand Rapids, Michigan
- Corewell Health Children's — Royal Oak, Michigan
Phase 3 Recruiting Network
Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT03550391
Sites in Michigan: - University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
Phase 2, Phase 3 Recruiting Academic/Other
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and …
Sponsor: Global Coalition for Adaptive Research
NCT ID: NCT03970447
Sites in Michigan: - Henry Ford Health System — Detroit, Michigan
Phase 2 Recruiting Network
This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binime…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT04511013
Sites in Michigan: - University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan
- Bronson Battle Creek — Battle Creek, Michigan
- University of Michigan - Brighton Center for Specialty Care — Brighton, Michigan
- Helen DeVos Children's Hospital at Spectrum Health — Grand Rapids, Michigan
- Spectrum Health at Butterworth Campus — Grand Rapids, Michigan
Phase 2 Recruiting Network
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to …
Sponsor: Children's Oncology Group
NCT ID: NCT04684368
Sites in Michigan: - C S Mott Children's Hospital — Ann Arbor, Michigan
- Children's Hospital of Michigan — Detroit, Michigan
- Michigan State University — East Lansing, Michigan
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital — Grand Rapids, Michigan
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital — Grand Rapids, Michigan
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…
Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in Michigan: - C S Mott Children's Hospital — Ann Arbor, Michigan
Phase 1, Phase 2 Recruiting Industry
The study treatment, BAY 3713372, is under development to treat MTAP (methylthioadenosine phosphorylase)-deleted solid tumors. It is thought to work by blocking the protein arginine N-methyltransferase 5 (PRMT5). This may kill the MTAP-del…
Sponsor: Bayer
NCT ID: NCT06914128
Sites in Michigan: - START | Midwest — Grand Rapids, Michigan
Phase 2 Recruiting Industry
This is an open-label, multicenter Phase 2 study evaluating BMS-986504 in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a monotherapy component and a combination component in which BM…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07492680
Sites in Michigan: - Local Institution - 0119 — Ann Arbor, Michigan
Phase 2 Recruiting Academic/Other
This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIP…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05096481
Sites in Michigan: - C.S. Mott Children's Hospital — Ann Arbor, Michigan
Phase 2 Recruiting Academic/Other
This is a Phase II open-label study to investigate the safety and efficacy of ACT001 in patients with DIPG and H3K27-altered HGG.
Sponsor: Nationwide Children's Hospital
NCT ID: NCT06838676
Sites in Michigan: - C.S. Mott Children's Hospital — Ann Arbor, Michigan
Phase 1, Phase 2 Recruiting Industry
This is a multi-site, global, open-label study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-positive, human epidermal growth factor re…
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT05386108
Sites in Michigan: - Henry Ford Hospital — Detroit, Michigan
Phase 2 Recruiting Academic/Other
The goal of this study is to determine the efficacy of the 1) ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (cell…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05843253
Sites in Michigan: - C.S. Mott Children's Hospital — Ann Arbor, Michigan
Phase 2 Recruiting Academic/Other
This is a multi-center, multinational phase 2 trial that aims to explore the use of molecular and clinical risk-directed therapy in treatment of children 0-4.99 years of age with newly diagnosed medulloblastoma.
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT05535166
Sites in Michigan: - C.S. MOTT Children's Hospital, University of Michigan — Ann Arbor, Michigan
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expansion (Phase 2). The study population i…
Sponsor: LigaChem Biosciences, Inc.
NCT ID: NCT05941507
Sites in Michigan: - University of Michigan — Ann Arbor, Michigan
Phase 2 Recruiting Academic/Other
Patients with with recurrent or progressive medulloblastoma, ependymoma, atypical teratoid rhabdoid tumor (ATRT), and CNS tumors of various histologies have a very poor prognosis whether treated with conventional chemotherapy, high-dose ch…
Sponsor: Medical University of Vienna
NCT ID: NCT01356290
Sites in Michigan: - Helen DeVos Children's Hospital — Grand Rapids, Michigan
Phase 1 Recruiting Industry
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
Sponsor: Iambic Therapeutics, Inc
NCT ID: NCT06253871
Sites in Michigan: - University of Michigan — Ann Arbor, Michigan
- Henry Ford Cancer Institute — Detroit, Michigan
- START - Midwest Cancer Research Center — Grand Rapids, Michigan
Phase 1 Recruiting Industry
The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma or astrocytoma is newly diagnosed, and to evaluate safety and tolerability of this combi…
Sponsor: Orbus Therapeutics, Inc.
NCT ID: NCT05879367
Sites in Michigan: - Henry Ford Hospital — Detroit, Michigan
Phase 1 Recruiting Industry
The purpose of this study is to assess the safety, tolerability and efficacy of the study drug AO-252 and identify the best dose for use in future studies.
Sponsor: A2A Pharmaceuticals Inc.
NCT ID: NCT06136884
Sites in Michigan: - Karmanos Cancer Institute — Detroit, Michigan
Phase 1 Recruiting Academic/Other
This phase I trial studies the effects and best dose of ONC206 alone or in combination with radiation therapy in treating patients with diffuse midline gliomas that is newly diagnosed or has come back (recurrent) or other recurrent primary…
Sponsor: Sabine Mueller, MD, PhD
NCT ID: NCT04732065
Sites in Michigan: - University of Michigan — Ann Arbor, Michigan
Phase 1 Recruiting Academic/Other
This phase I trial investigates the side effects of chemotherapy and cellular immunotherapy in treating children with IL13Ralpha2 positive brain tumors that have come back after a period of improvement (recurrent) or do not respond to trea…
Sponsor: City of Hope Medical Center
NCT ID: NCT04510051
Sites in Michigan: - C.S. Mott Children's Hospital, University of Michigan — Ann Arbor, Michigan
Phase 1 Recruiting Academic/Other
The primary goal of this Phase I study is to determine the maximum tolerated dose of oncolytic adenovirus mediated double suicide-gene therapy in combination with fractionated stereotactic radiosurgery in patients with recurrent high-grade…
Sponsor: Henry Ford Health System
NCT ID: NCT05686798
Sites in Michigan: - Henry Ford Health System — Detroit, Michigan
Phase 1 Recruiting Academic/Other
This phase I trial tests the safety, side effects and best dose of AdV-HSV1-TK and AdV-Flt3L in combination with valacyclovir for the treatment of patients with primary cancerous (malignant) brain tumors that can be removed by surgery (res…
Sponsor: University of Michigan Rogel Cancer Center
NCT ID: NCT06914479
Sites in Michigan: - University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan